Dysport (abobotulinumtoxin A) administered at a dose two times higher than that of Botox (onabotulinumtoxin A) is a cost-effective option to treat children with cerebral palsy, a study shows.

Published in the European Journal of Pediatric Neurology, a prospective, real-world study showed Dysport, when given at a two-fold higher unit dose than Botox, is safe and equally effective in improving muscle function and reducing pain, while significantly reducing treatment-associated costs.